So let’s say you are a leading multinational pharmaceutical company and you have a blockbuster cancer drug. You patent the drug, make tremendous profits, but now the clock is ticking and the patent is set to expire. What do you do? If you are Novartis and your blockbuster cancer drug is Gleevec you are going [...]